• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast
Share
Announcements, News, ProteaseTag®

ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast

May 10, 2017
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for exclusive intellectual property rights for its ProteaseTag® technology. This technology enables the measurement of active protease biomarkers of disease. Following its spin out from Queen’s in 2013, the two parties agreed an initial licence for the first generation of ProteaseTags®, enabling ProAxsis to commercialise its first product. This laboratory-based immunoassay for the measurement of neutrophil elastase as a biomarker of lung infection and inflammation in chronic respiratory diseases was successfully registered with a CE Mark in September 2016.

Commenting on the news, Dr. David Ribeiro, CEO of ProAxsis, said: “Despite now being based in a new purpose-built laboratory at Catalyst Inc., we continue to maintain strong links with Queen’s, and we’re very pleased to have signed this licensing agreement. These modified ProteaseTags® are more suited to some of our ongoing protease biomarker targets and the company looks forward to launching further immunoassays and point-of-care tests in the near future.”

Mr Brian McCaul, Director of Innovation at Queen’s and CEO of QUBIS Ltd commented: “ProAxsis remains strongly poised to transform point-of-care diagnostics for chronic diseases. We are pleased to continue to support one of our own spin out companies by licensing out a new innovative technology which will enhance their current product offering.”

The technology behind the ProAxsis ProteaseTag® was initially developed in the School of Pharmacy at Queen’s, by a team led by Dr. Lorraine Martin and Prof. Brian Walker. Further information on research at Queen’s can be found at www.qub.ac.uk/research.

Queries regarding ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using its proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

May 10, 2017
No comments yet

Related News

Other posts that you should not miss.
News

ProAxsis shortlisted for Small Business of the Year Award

November 18, 2019
-
Posted by David Ribeiro

ProAxsis is delighted to have been shortlisted for a Business Eye First Trust Award for the second …

Read More
November 18, 2019
Posted by David Ribeiro
Announcements, News

NetScientific acquires 100% control of portfolio company ProAxsis Limited

October 16, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, …

Read More
October 16, 2020
Posted by David Ribeiro
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay

September 30, 2016
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel …

Read More
September 30, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis technology highlighted in AJRCCM editorial
NEXT POST →
ProAxsis abstracts at 2017 American Thoracic Society Conference

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast - ProAxsis